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EDITORIAL
Reducing stigma and discrimination: new evidence
and its implications
Janet Seeleya and Ann K. Blancb
AIDS 2020, 34 (Suppl 1):S1–S4
Writing in 2005, Castro and Farmer [1] observed that a
‘transformation of AIDS from an inevitably fatal disease to
a chronic and manageable one has decreased stigma
dramatically in Haiti’ (p.57). Fifteen years later, hopes that
biomedical advances could end HIV-related stigma seem
distant. Stigma persists and is made manifest in different
ways and at different times in the lives of people living
with HIV (PLHIV) [2,3], by whole communities affected
by a high burden of HIV-infection [4], and is mirrored in
the ways in which people react to new disease threats [5].
Stigma may indeed have reduced in some forms [6,7], but
gains from HIV-stigma reduction initiatives have often
been modest [6,8] and are rarely implemented at scale [9].
The impact of stigma and discrimination continues to be
seen in the variable uptake of HIV-testing and access to
care and support [10,11]. The heterogeneity in response
to universal test and treat initiatives, and the role different
types of stigma play in this response, has been seen in
many settings [12]. Context matters in the effectiveness of
stigma-reduction interventions as men and women, older
and younger, respond differently to efforts to address
stigma and discrimination [13]. These differences present
a continued challenge for standardized stigma measures to
facilitate comparisons between different approaches to
intervention [14], and the ways in which data on stigma
are interpreted [15]. In this collection, we bring together
articles that address innovation in stigma measurement,
speak to the importance of understanding context in
intervention design and implementation and highlight
the emergence (or re-emergence) of different forms of
stigma that have a profound impact on how individuals
and groups of people engage with HIV-services. There
are reasons to hope that further progress is possible, but
also reminders of how fragile success may be in the face of
resource constraints and other urgent health priorities.
We have grouped the articles to present those that address
the measurement of stigma first, before moving to articles
which provide programmatic insights and evidence of
impact. The articles cover a diversity of populations that
experience stigma across a range of geographic settings
and epidemic context.
Several of the articles in this collection contribute to
advances in measurement and, in particular, to the update
of the PLHIV Stigma Index, which was originally
developed in 2008 [16]. The process of updating and the
resulting Stigma Index 2.0 are described by Friedland et
al. Notable improvements to the Index include new and
refined questions on gender identity, key population
membership and other marginalized groups, interactions
with healthcare services, anxiety and depression, and
internalized stigma. A PLHIV Resilience Scale was also
added. The Index was also adjusted to be more reflective
of the current context of the epidemic and the response,
incorporating indicators that allow a better understanding
of intersectional stigma and take advantage of psycho-
metric testing.
Importantly, the Stigma Index 2.0 has been tested and
validated across a range of settings, including Cameroon,
Senegal, and Uganda. The incorporation of formal
statistical techniques for assessing the validity of measures
is reflected in the internalized stigma scale across four
countries described by Geibel et al. and the Resilience
Scale across three countries described by Gottert et al.
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Broady et al. and Lyons et al. present new evidence on
the conceptualization and measurement of ‘stigma by
association’ and intersectional stigma, respectively.
The value of getting measurement right and document-
ing the ways in which data are used to improve policies
and programs is clearly illustrated in the article by
Siraprapasiri et al. who highlight the use of data to address
stigma and discrimination as one of the ‘three building
blocks’ in the national response to HIV/AIDS in
Thailand. Specifically, indicators of stigma and discrimi-
nation were incorporated into the national monitoring
and evaluation plan, and a systematic surveillance system
was put in place for tracking progress in health facilities,
among key populations, and in the general population.
The intentional use of measurement is also one of the
themes of the article by Nyblade et al. They emphasize the
importance of the formative research that was used to
catalyze action in district level health facilities in Tanzania
and Ghana and to inform the design of actions to address
stigma. They also describe the integration of stigma
measures into performance management systems to track
success and make course corrections.
A commitment to participatory research and processes
contributed to the success of several of the initiatives
described here, including the revision of the Stigma Index
driven and administered by PLHIV, the implementation
of the Total Facility Approach to reducing stigma in
health facilities which utilized participatory workshops
with key stakeholders to adapt measurement tools, and in
the scale up of stigma interventions in Thailand where
stakeholders including PLHIV, key populations, local and
international NGOs, development partners and govern-
ment representatives participated in all stages of the
process.
That the experience of stigma (whether due to HIV status
or key population status) is both an outcome in its own
right with a range of determinants – an indicator of health
and wellbeing – as well as a determinant of other health
outcomes related to HIV (e.g., incidence, treatment
adherence, viral suppression) is tested in several of the
articles. For example, Yam et al. show that while results
were not completely consistent across communities,
PLHIV who were also members of a key population
group were significantly more likely to experience some
types of stigma and to experience worse treatment
outcomes. Geibel et al. show that internalized stigma is
associated with depression as well as with antiretroviral
therapy (ART) use and viral suppression. Broady et al.
demonstrate that experiencing ‘stigma by association’
among Australian gay and bisexual men (whether LHIV
or not) has a cross-sectional relationship to several
characteristics including the strength of attachment to the
community and that this type of stigma is associated with
the likelihood of HIV testing and psychological distress.
There is encouraging new evidence about interventions
that have shown success in reducing stigma and
approaches that may be transferable to other settings.
For example, interventions aimed at reducing stigma
communicated or enacted by health workers have proven
to be effective in Ghana and Tanzania (Nyblade et al.) as
well as in Thailand (Siraprapasiri et al.). Both efforts
conclude that a ‘total facility’ effort – one that includes
both clinical and nonclinical staff – is likely to be most
effective at reducing stigma.
Similarly, articles in this collection add to the existing
evidence that efforts to reduce stigma experienced by
PLHIV are likely to be most effective if interventions
occur at multiple levels and in multiple ways. Singh et al.
undertook research which explicitly tested and found
positive effects of a multilevel approach in India, in which
individual, group, and collective interventions were
introduced in three different sequences. The randomized
controlled trial (RCT) described by Ibrahim et al. on
ART adherence among people newly initiating care in
the United States points to the need to customize
interventions for those who are new to treatment and
those who are more experienced. In addition, while the
intervention centered on individual level counseling for
addressing internalized stigma, it also offered ‘informa-
tion, motivation, and behavioral skills for adherence to
care and ART, focusing on adjustment, problem solving,
affect management, and communication.’ The authors
conclude that multifaceted interventions can be effective
but point to the need for studies that can provide
evidence on which interventions are most effective for
which people. The results of the RCT described by
Lyons et al. underscores the need to address multiple
intersecting forms of stigma and multiple identities.
While not testing an intervention, Gottert et al.
demonstrate in their findings that the determinants of
resilience among PLHIVoperate at individual, interper-
sonal, and structural/policy levels (such as legal protec-
tions for PLHIV), suggesting that interventions would be
most effective if they were designed to address these
multiple levels also.
As highlighted in the article describing Thailand’s HIV/
AIDS national response, treatment outcomes are also
influenced by service delivery issues not related to stigma.
The barriers to treatment that are generated by a lack of
access to high-quality health services (including trained
health workers, drugs and supplies, testing, counseling)
need to be overcome in parallel with stigma reduction. The
absence of comprehensive models that aim to sort out the
relative contributions of each may be due to thedemanding
data requirements, but it is difficult to assess the significance
of stigma reduction efforts in their absence. An example is
provided by Yam et al. who did not find an association
between stigma and either viral suppression or missing an
ART dose among PLHIV of Haitian descent. They
hypothesize that the undocumented status of many in that
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group may inhibit their access to health services more than
HIV-related stigma.
Despite the methodological and substantive advances
presented in these articles, several challenges remain for
the study of HIV-related stigma. The need to employ
nonprobabilistic sampling methods, especially for key
populations, due to the barriers to usual probabilistic
techniques remains difficult to overcome. As noted by
Gottert et al., one problem is that techniques such as
snowball and respondent driven sampling (RDS) may
result in an overrepresentation of people linked to care,
and it is difficult to assess the effect of nonrepresentative
sampling on the results. While sampling issues are noted
by several authors as a limitation of the research there is
little attempt to gauge their effects. More comprehensive
assessments of the potential biases should become
standard in research that uses nonprobability samples. It
is worth noting that this type of sampling (RDS,
snowball) may become more difficult during/post the
COVID-19 pandemic when the frequency of in-person
interaction is likely to be reduced; more alternatives to
these methods are urgently needed.
To understand the independent causal effects of inter-
ventions on stigma and HIV-related outcomes or simply
the causal effects of stigma on HIV treatment outcomes,
more studies with rigorous designs are needed. This
collection includes two RCTs of interventions (Ibrahim
et al. and Singh et al.). Due to their rigorous designs, these
studies make substantial contributions to our understand-
ing of the effects of complex interventions. However,
because, as with many such trials, participants are not
followed poststudy we learn little about the durability of
the effects of the interventions. More investment in
longer periods of study is sorely needed. Cross-sectional
data, as the authors of these articles acknowledge, yield
ambiguous results on direction of causality (Yam, Gottert,
Broady, Geibel). The one longitudinal study in the
collection (Lyons et al.) is able to showcase the advantages
of this type of data by tracking incidence and viral
suppression over time – and linking these outcomes to
changes in stigma.
Finally, only one article in the supplement includes
qualitative data (Geibel et al.); the data provide insights
that improve our understanding of, in this case, the
reaction of participants to the internalized stigma subscale
of the Stigma Index 2.0. Overall, however, research using
qualitative approaches to better understand the experi-
ence of stigma and of related interventions would be a
useful addition to many quantitative studies and trial
designs [17].
All of the articles in this collection serve to highlight the
persistence of HIV-related stigma, while ways in which
stigma is experienced and shown may change with time,
the ‘third epidemic’, to use the words of Mann [18],
remains a stubborn obstacle to testing, treatment, and care
for too many people around the world.
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